{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:54:27Z","timestamp":1791687267459,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01298-9","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:44:47Z","timestamp":1788893087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Novel Neutralizing-antibody Assay for Detection of \u03b2-NGF Binding Domain\u2013specific Antibodies Against a \u03b2-NGF\/TNFR2 Bispecific Therapeutic Antibody"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4176-5185","authenticated-orcid":false,"given":"Nellie","family":"Moshkovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3450-3295","authenticated-orcid":false,"given":"Anish","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7552-3485","authenticated-orcid":false,"given":"Enowmpey","family":"Enowtambong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5587-328X","authenticated-orcid":false,"given":"Surekha R.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7683-3231","authenticated-orcid":false,"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1132-9015","authenticated-orcid":false,"given":"Weiping","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"4","key":"1298_CR1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2174\/1389201023378175","volume":"3","author":"E Koren","year":"2002","unstructured":"Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans\u2014clinical significance, assessment and prediction. Curr Pharm Biotechnol. 2002;3(4):349\u201360.","journal-title":"Curr Pharm Biotechnol"},{"key":"1298_CR2","doi-asserted-by":"crossref","unstructured":"Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24(11):1720\u201340; discussion 19.","DOI":"10.1016\/S0149-2918(02)80075-3"},{"key":"1298_CR3","unstructured":"US Food and Drug Administration. Guidance for industry: immunogenicity testing of therapeutic protein products \u2014developing and validating assays for anti-drug antibody detection. 2019."},{"issue":"5","key":"1298_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","volume":"48","author":"G Shankar","year":"2008","unstructured":"Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267\u201381.","journal-title":"J Pharm Biomed Anal"},{"issue":"1\u20132","key":"1298_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2008.01.001","volume":"333","author":"E Koren","year":"2008","unstructured":"Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333(1\u20132):1\u20139.","journal-title":"J Immunol Methods"},{"issue":"3","key":"1298_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.yrtph.2007.07.005","volume":"49","author":"HW Smith","year":"2007","unstructured":"Smith HW, Butterfield A, Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul Toxicol Pharmacol. 2007;49(3):230\u20137.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1298_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jim.2017.04.002","volume":"446","author":"H Niu","year":"2017","unstructured":"Niu H, Klem T, Yang J, Qiu Y, Pan L. A biotin-drug extraction and acid dissociation (BEAD) procedure to eliminate matrix and drug interference in a protein complex anti-drug antibody (ADA) isotype specific assay. J Immunol Methods. 2017;446:30\u20136.","journal-title":"J Immunol Methods"},{"key":"1298_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jim.2018.08.003","volume":"462","author":"W Xu","year":"2018","unstructured":"Xu W, Sank M, Cummings J, Carl S, Juhel M, Gleason C, et al. Bead-extraction and heat-dissociation (BEHD): a novel way to overcome drug and matrix interference in immunogenicity testing. J Immunol Methods. 2018;462:34\u201341.","journal-title":"J Immunol Methods"},{"issue":"1","key":"1298_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1208\/s12248-023-00783-9","volume":"25","author":"D Wickramarachchi","year":"2023","unstructured":"Wickramarachchi D, Wagner J, Woo T, Ferrari F, Steinmetz T, Helmy R, et al. A novel neutralization antibody assay method to overcome drug interference with better compatibility with acid-sensitive neutralizing antibodies. AAPS J. 2023;25(1):18.","journal-title":"AAPS J"},{"key":"1298_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116006","volume":"241","author":"R Fu","year":"2024","unstructured":"Fu R, Xu J, Guo Q, Liu T, Su X, Xu M, et al. Highly drug\/target-tolerant neutralizing antibody (NAb) assay development through target-based drug depletion and drug-based NAb extraction for an anti-EGFR therapeutic monoclonal antibody. J Pharm Biomed Anal. 2024;241:116006.","journal-title":"J Pharm Biomed Anal"},{"key":"1298_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jim.2017.04.002","volume":"446","author":"H Niu","year":"2017","unstructured":"Niu H, Klem T, Yang J, Qiu Y, Pan L. A biotin-drug extraction and acid dissociation (BEAD) procedure to eliminate matrix and drug interference in a protein complex anti-drug antibody (ADA) isotype specific assay. J Immunol Methods. 2017;446:30\u20136.","journal-title":"J Immunol Methods"},{"key":"1298_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.09.020","author":"G Shankar","year":"2008","unstructured":"Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008. https:\/\/doi.org\/10.1016\/j.jpba.2008.09.020.","journal-title":"J Pharm Biomed Anal"},{"issue":"1\u20132","key":"1298_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","volume":"289","author":"AR Mire-Sluis","year":"2004","unstructured":"Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1\u20132):1\u201316.","journal-title":"J Immunol Methods"},{"issue":"1\u20132","key":"1298_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","volume":"289","author":"AR Mire-Sluis","year":"2004","unstructured":"Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1\u20132):1\u201316.","journal-title":"J Immunol Methods"},{"issue":"6","key":"1298_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/0063030-200822060-00002","volume":"22","author":"JJ Watson","year":"2008","unstructured":"Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs. 2008;22(6):349\u201359.","journal-title":"BioDrugs"},{"issue":"22","key":"1298_CR16","first-page":"4172","volume":"10","author":"LF Reichardt","year":"1971","unstructured":"Reichardt LF, Shooter EM. Dimerization and dissociation properties of nerve growth factor in solution. Biochemistry. 1971;10(22):4172\u20137.","journal-title":"Biochemistry"},{"key":"1298_CR17","unstructured":"Scientific T. NanoDrop microvolume spectrophotometers and fluorometers applications [Available from: https:\/\/www.thermofisher.com\/nanodrop."},{"key":"1298_CR18","unstructured":"US Food and Drug Administration. Guidance for industry: immunogenicity assessment for therapeutic protein products. 2014."},{"issue":"4","key":"1298_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299\u2013316.","journal-title":"BioDrugs"},{"key":"1298_CR20","unstructured":"Ilinskaya A, Jeffries E, Kulagina N. Mitigation strategy for eliminating NAb-arm-2 false negative response due to drug-NAb-arm-1 complex interference for a bi-specific therapeutic. Workshops on Recent Issues in Bioanalysis. New Orleans, LA2025. 2025."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01298-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01298-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01298-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:03:01Z","timestamp":1790665381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01298-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1298"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01298-9","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are employees of AstraZeneca and may hold stock ownership, options, and\/or interests in the company.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"138"}}